Fifth patient conversion in INSPIRE study of the Neuro-Spinal Scaffold™ outstrips objective performance criteria
InVivo’s Neuro-Spinal Scaffold study could soon change status from pilot to pivotal probable benefit
InVivo Therapeutics reports significant improvement of first patient Implanted with Neuro-Spinal Scaffold™
Two and a half months after the previous case, InVivo is now reporting the news that its spinal scaffold has been used in another study patient
It was slated to happen in March, and it’s undeniably a slow process, but InVivo Therapeutics is nudging forward with its pivotal study
Recent acceleration of its clinical program suggests the spinal solutions company is back on track
2014 was a rollercoaster for the spinal scaffold developer, as the pilot study looked like it would take forever. That’s changed.
Barely a week after re-opening the study doors to a second patient, one not-so-lucky individual has sustained a multi-trauma injury that fits the bill
InVivo Therapeutics has been given the green light to reopen subject enrollment for the pilot trial of its investigational Neuro-Spinal Scaffold in patients with acute spinal cord injury
It looks like the company has been working hard with the FDA as they’ve agree to allow expedited patient enrollment
The FDA has approved various changes to the protocol for InVivo’s ongoing IDE pilot trial for its acute spinal cord injury scaffold.
Embattled spinal scaffold developer, InVivo Therapeutics looks like it’s got a hold of its finances as it proceeds down the rocky road through trials to ultimate approval.
Getting a new technology to market is an expensive undertaking, and often painful too as InVivo Therapeutics is finding out as it ditches an R&D project and 28% of its staff while its Neuro-Spinal Scaffolds go through a lengthy regulatory approval process.
Less than a month ago we covered the news that InVivo Therapeutics Holdings Corp. was ready to start the first trial of its Neuro-Spinal Scaffold. Now the biomaterials company has reported financial results for the quarter ended March 31, 2014 and updated us on its business
Preclinical testing has shown promise that InVivo’s clever scaffold might just provide the structural support necessary to permit spinal cord regeneration. The recently FDA-approved study should provide enough safety and efficacy data to give us a real clue as to its potential.
It’s all happening at InVivo Therapeutics. In a flurry of news releases the company has appointed a new CEO, gained conditional approval to commence its US trial and gone ahead and satisfied the conditions with a series of responses to the FDA’s outstanding issues. The study will commence with first patients in early March.